CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027

List of Tables

CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027 Report Highlights:

Currently No Drug Commercially Available In Market
More Than 80 Drugs In Clinical Trials
Highest Clinical Trials Phase: Phase II (7 Drugs)
CD137 Drugs Market Opportunity In Initial 24 Months Of Launch: > US$ 400 Million
Global & Regional Trends (Clinical & Commercial)
CD137 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
CD137 Therapeutic Approaches By Antibodies Classification
Role Of CD137 & Clinical Progress By Indication

CD137, also known as 4-1BB, has emerged as a promising target for cancer immunotherapy in recent years. The potential of CD137-targeted therapies lies in their ability to stimulate and expand cytotoxic T cells leading to improved tumor cell killing and long-lasting immune memory. As a result, the field has gained attention from researchers and pharmaceutical companies alike, with several research publications hinting at a promising future for this cancer therapeutic approach. Moreover, data emerging from early clinical trials have already begun demonstrating therapeutic benefits, providing real-time validation of CD137-targeted drug development.

With no licensed medications currently on the market, CD137-targeted therapies are still in their infancy. Nonetheless, there is an abundance of candidates in the pipeline in different phases of clinical development, with phase 2 being the highest. Several major pharmaceutical companies and biotech firms, including BioNTech, Genmab, Adagene, and Shanghai Henlius Biotech, are actively pursuing drug development programs after recognizing the potential of this target. This presents a significant opportunity for both established players and newcomers in the field of immuno-oncology.

The ability of CD137-targeted treatments to get past some of the drawbacks of existing immunotherapies, like immune checkpoint inhibitors, is one of their main advantages. Although checkpoint inhibitors have fundamentally altered the way that cancer is treated, only a small percentage of patients and cancer types respond well to them. The range of individuals who can benefit from immunotherapy may be increased by CD137 agonists, which may enhance or supplement the effectiveness of these currently available treatments.

The most advanced CD137-targeted therapies in clinical development are agonistic antibodies. The intended effect of these compounds is to stimulate T cell survival, proliferation, and effector activities via activating CD137 signaling. Regarding anti-tumor effectiveness and safety characteristics, early clinical trials have produced encouraging results. YH004, ADG106, ADG206, and ATOR-1017 are a few CD137 agonistic antibodies that are now undergoing clinical trials. There have been challenges, nevertheless, such as dose-limiting hepatotoxicity seen in certain candidates. Due to this, other strategies are being investigated that might provide better safety and efficacy profiles, such as bispecific antibodies and tailored ligands.

Combining CD137-targeted therapies with other immunomodulatory drugs is one highly intriguing area of investigation. CD137 agonists have been shown to have synergistic benefits when paired with checkpoint inhibitors, chemotherapy, targeted therapy, or even radiation therapy, according to preclinical research and early phase clinical evidence. These combination approaches may result in more potent and more persistent anti-tumor responses, which would fulfill the unmet demand for efficient treatments for malignancies that are challenging to treat.

The market potential for effective CD137 antibodies is significant, considering the wide range of applications of CD137-targeted treatments in cancer. New and efficient treatment modalities are highly sought after, as the global market for cancer immunotherapy is expected to grow to many billions of dollars in the next several years. A sizeable portion of this market may be taken up by CD137-targeted treatments, especially if they show greater efficacy and can treat conditions where immunotherapies have not been very successful.

Furthermore, the versatility of CD137 as a target extends beyond oncology. Recent studies point to possible uses in transplantation, autoimmune diseases, inflammatory disorders, and infectious diseases. This wide-ranging therapeutic potential could open up additional market opportunities for drug developers, willing to explore these indications.

Despite the promising outlook, several challenges need to be addressed in the development of CD137-targeted therapies. These include optimizing dosing regimens to balance efficacy and safety, identifying predictive biomarkers for patient section, and developing strategies to overcome potential resistance mechanisms. Overcoming these hurdles will be crucial for the successful translation of CD137-targeted therapies from bench to bedside.

In conclusion, CD137-targeted therapies represent a significant opportunity to transform treatment of cancer and various other diseases involving the immune system. The increasing comprehension of CD137 biology, in conjunction with developments in antibody engineering and combination strategies, offers a robust basis for novelty in this domain. CD137-targeted therapies have the potential to fill a significant gap in the medical community and gain a significant portion of the cancer immunotherapies market, which presents a strong case for development and innovation.

1. Brief Introduction To CD137

1.1 Clinical Overview
1.2 Biological History Of CD137
1.3 CD137 Hosting An Era Of Agonists Over Antagonists
1.4 Bi-Directional Signaling In CD137

2. Global CD137 Antibody Market Outlook

2.1 Current Research & Market Scenario
2.2 Future Commercialization Opportunities

3. CD137 Antibody Clinical Developments by Regions

3.1 China
3.2 US
3.3 South Korea
3.4 Europe
3.5 Australia

4. Role Of CD137 & Clinical Progress By Indication

4.1 Cancer
- 4.1.1 Leukemia
- 4.1.2 Lymphoma
- 4.1.3 Lung Cancer
- 4.1.4 Melanoma
- 4.1.5 Breast Cancer
- 4.1.6 Colorectal Cancer
4.2 Autoimmune & Inflammatory Diseases
4.3 Microbial Infections
- 4.3.1 Viral Infections
- 4.3.2 Bacterial infections

5. Global CD137 Antibodies Clinical Trials Overview

5.1 By Company
5.2 By Country
5.3 By Indication
5.4 By Phase
5.5 By Patient Segment

6. CD137 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II

7. CD137 Targeting Proprietary Technology Platforms By Companies

8. CD137 Therapeutic Approaches By Antibodies Classification

8.1 Monoclonal Antibody Based Strategies
8.2 Bispecific Antibody Centered Approaches
8.3 Trispecific Antibody Established Strategies
8.4 Tetraspecific Antibody Strategies

9. Combination Therapies With CD137 Antibodies

10. Competitive Landscape

10.1 ABL Bio
10.2 Adagene
10.3 Alligator Bioscience
10.4 BeiGene
10.5 Bicycle Therapeutics
10.6 BioNTech
10.7 Biotheus
10.8 Crescendo Biologics
10.9 Eutilex
10.10 F-star Therapeutics
10.11 Genmab
10.12 I-MAB Biopharma
10.13 Lyvgen Biopharma
10.14 OriCell Therapeutics
10.15 Pieris Pharmaceuticals
10.16 Shanghai Henlius Biotech
10.17 Sichuan Baili Pharmaceutical
10.18 SystImmune

List of Figures

Figure 1-1: Anti-CD137 Monoclonal Antibody - Immune Regulation Mechanisms
Figure 1-2: Schematic Depiction Of Bidirectional Signaling By CD137-CD137L
Figure 2-1: CD137 First Approval Sales Estimate - First 12 Months & First 24 Months (US$ Million)
Figure 4-1: GNC-035-105 Phase Ib/II (NCT05944978) - Initiation & Completion Year
Figure 4-2: GNC-035-101 Phase I (NCT05944978) - Initiation & Completion Year
Figure 4-3: GNC-038-101 Phase I (NCT04606433) - Initiation & Completion Year
Figure 4-4: ACIT001 Phase Ib/II (NCT03938987) - Initiation & Completion Year
Figure 4-5: BP41072 Phase I/II (NCT04077723) - Initiation & Completion Year
Figure 4-6: YH004 Phase I (NCT05564806) - Initiation & Completion Year
Figure 4-7: EU-CTS101-I-01 Phase I/II (NCT04903873) - Initiation & Completion Year
Figure 4-8: GCT1046-04 Phase 2 (NCT05117242) - Initiation & Completion Year
Figure 4-9: GCT1046-04 Phase 2 (NCT05117242) - Initiation & Completion Year
Figure 4-10: GCT1046-04 Phase II (NCT05117242) - Initiation & Completion Year
Figure 4-11: Phase I/II (NCT03809624) - Initiation & Completion Year
Figure 4-12: INBRX-105 Phase I (NCT03809624) - Initiation & Completion Year
Figure 4-13: C-1100-01 Phase I (NCT04121676) - Initiation & Completion Year
Figure 4-14: QLF31907-201 Phase 2 (NCT05823246) - Initiation & Completion Year
Figure 4-15: AVIATOR Phase 2 (NCT03414658) - Initiation & Completion Year
Figure 4-16: ADG106-T6002 Phase 1/2 (NCT05275777) - Initiation & Completion Year
Figure 4-17: YH32367-101 Phase I/II (NCT05523947) - Initiation & Completion Year
Figure 4-18: GNC-035-103 Phase 1 (NCT05160545) - Initiation & Completion Year
Figure 4-19: BP42675 Phase Ib (NCT04826003) - Initiation & Completion Year
Figure 4-20: EU-CTS101-I-01 Phase I/II (NCT04903873) - Initiation & Completion Year
Figure 4-21: 2017-0180 Phase 1 (NCT03290937) - Initiation & Completion Year
Figure 5-1: Global - CD137 Targeting Antibodies Clinical Pipeline by Company (Numbers), 2024
Figure 5-2: Global - CD137 Targeting Antibodies Clinical Pipeline by Country (Numbers), 2024
Figure 5-3: Global - CD137 Targeting Antibodies Clinical Pipeline by Indication (Numbers), 2024
Figure 5-4: Global - CD137 Targeting Antibodies Clinical Pipeline by Phase (Numbers), 2024
Figure 5-5: Global - CD137 Targeting Antibodies Clinical Pipeline by Patient Segment (Numbers), 2024
Figure 7-1: Adagene - Anti CD137 NEObody ACG106
Figure 7-2: Adagene - Anti CD137 POWERbody ADG206
Figure 7-3: Genmab - DUObody Production Process
Figure 7-4: Crescendo Biologics - Humabody Structure
Figure 7-5: Crescendo Biologics - CB307 Structure
Figure 7-6: Numab Therapeutics - MATCH Format
Figure 7-7: Systimmune - GNC-039 Structure
Figure 7-8: Systimmune - GNC-035 Structure
Figure 7-9: Systimmune - GNC-038 Structure
Figure 7-10: Merus - Multiclonics Structure
Figure 7-11: Chugai Pharmabody Research - Dual-Ig(R) Technology
Figure 7-12: Eutilex - Costim Platform Technology
Figure 8-1: ATOR-1017 - Mechanism Of Action
Figure 8-2: EU101 - Mode Of Action
Figure 8-3: LVGN6051 - Mechanism Of Action
Figure 8-4: ABL503 - Structure & Mechanism Of Action
Figure 8-5: FS120 - Improving PD-1 & Chemotherapy Responses
Figure 8-6: MP0310 - Mechanism Of Action

List of Tables

Table 4-1: Lymphoma - Clinical Trials Underway for GNC-038 & GNC-035
Table 8-1: Bispecific Antibodies Targeting CD137/4-1BB in Clinical Trials
Table 8-2: Trispecific Antibodies Targeting CD137/4-1BB in Clinical Trials
Table 8-3: Tetraspecific Antibodies Targeting CD137/4-1BB in Clinical Trials
Table 9-1: Ongoing Clinical Trials Evaluating CD137 Antibody Combinations

CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027

Description

Table of Contents

List of Tables

Table of Contents

1. Brief Introduction To CD137

2. Global CD137 Antibody Market Outlook

3. CD137 Antibody Clinical Developments by Regions

4. Role Of CD137 & Clinical Progress By Indication

5. Global CD137 Antibodies Clinical Trials Overview

6. CD137 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

7. CD137 Targeting Proprietary Technology Platforms By Companies

8. CD137 Therapeutic Approaches By Antibodies Classification

9. Combination Therapies With CD137 Antibodies

10. Competitive Landscape

List of Figures

List of Tables